Comparative Outcomes and Surgical Timing for Operative Fragility Hip Fracture Patients during the COVID-19 Pandemic: A Retrospective Cohort Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 610 KB, PDF-dokument

  • Katherine A. Rowe
  • Kiryung Kim
  • Nathan H. Varady
  • Marilyn Heng
  • Von Keudell, Arvind Gabriel
  • Michael J. Weaver
  • Ayesha Abdeen
  • Edward K. Rodriguez
  • Antonia F. Chen

The COVID-19 pandemic had wide-reaching effects on healthcare delivery, including care for hip fractures, a common injury among older adults. This study characterized factors related to surgical timing and outcomes, length-of-stay, and discharge disposition among patients treated for operative hip fractures during the first wave of the COVID-19 pandemic, compared to historical controls. A retrospective, observational cohort study was conducted from 16 March–20 May 2020 with a consecutive series of 64 operative fragility hip fracture patients at three tertiary academic medical centers. Historical controls were matched based on sex, surgical procedure, age, and comorbidities. Primary outcomes included 30-day mortality and time-to-surgery. Secondary outcomes included 30-day postoperative complications, length-of-stay, discharge disposition, and time to obtain a COVID-19 test result. There was no difference in 30-day mortality, complication rates, length-of-stay, anesthesia type, or time-to-surgery, despite a mean time to obtain a final preoperative COVID-19 test result of 17.6 h in the study group. Notably, 23.8% of patients were discharged to home during the COVID-19 pandemic, compared to 4.8% among controls (p = 0.003). On average, patients received surgical care within 48 h of arrival during the COVID-19 pandemic. More patients were discharged to home rather than a facility with no change in complications, suggesting an opportunity for increased discharge to home.

OriginalsprogEngelsk
Artikelnummer84
TidsskriftGeriatrics (Switzerland)
Vol/bind7
Udgave nummer4
Antal sider11
DOI
StatusUdgivet - 2022
Eksternt udgivetJa

Bibliografisk note

Funding Information:
One or more of the authors (M.H.) has received funding from AO Trauma. M.H. has or may receive payments or benefits from Zimmer-Biomet Inc. A.G.v.K. has or may receive payments or benefits from Stryker. M.J.W. has or may receive payments or benefits from OsteoCentric. A.A. has or may receive payments or benefits from Pfizer-Lilly, Brixtion Biosciences, and Advance Medical/Teladoc. A.F.C. has or may receive payments or benefits from SLACK publishing; Joint Purification Systems; Stryker; bOne; Sonoran Biosciences; Graftworx; Pfizer; Avanos; Irrisept; Convatec; 3M; Recro; Heraeus; Hyalex; DePuy—Ethicon; The Journal of Bone and Joint Surgery; GLG; UpToDate; Guidepoint; Adaptive Phage Therapeutics; and BICMD. For the remaining authors, no conflicts of interest are declared.

Publisher Copyright:
© 2022 by the authors.

ID: 343208764